XBiotech Inc. (NASDAQ:XBIT) fell 8.6% on Tuesday . The company traded as low as $17.08 and last traded at $17.69, with a volume of 1,095,517 shares traded. The stock had previously closed at $19.35.

A number of equities research analysts have issued reports on the stock. Noble Financial reaffirmed a “buy” rating and issued a $30.00 price objective (up from $24.00) on shares of XBiotech in a research report on Tuesday, June 28th. Zacks Investment Research raised shares of XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Tuesday, May 24th.

The stock has a 50 day moving average price of $17.13 and a 200 day moving average price of $11.78. The stock’s market capitalization is $586.51 million.

In related news, Director W Thorpe Mckenzie bought 20,000 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were purchased at an average price of $13.96 per share, with a total value of $279,200.00. Following the purchase, the director now owns 3,898,600 shares of the company’s stock, valued at approximately $54,424,456. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.